IFM Therapeutics Has an Unprecedented Track Record
Among the team's achievements in the company's first 3.5 years has been the progression of 3 novel programs from the standing start through to the clinic and the closing of 2 major deals.
IFM Therapeutics founded to discover agonists of NLRP3 for cancer.
Novel and proprietary NLRP3 agonist leads identified
Novel and proprietary STING agonists discovered
IFM Therapeutics's $27M Series A closed
Preclinical PoC for both NLRP3 and STING agonists demonstrated
$2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched
BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222
IFM Tre's $31M Series A financing closed (focus on NLRP3 antagonist)
IFM Due launched (focus on cGAS/STING antagonists)
IFM Tre dosed initial subject with first-in-class NLRP3 antagonist, IFM-2427
BMS dosed first patient with STING agonist, IFM-1364
$1.575B sale of IFM Tre to Novartis closed
IFM Quattro and IFM Discovery launched with $55.5M financing from Omega Funds, Atlas Venture and Abingworth
Meet Our Team
We have assembled an internal team—leading scientists and physician-scientists matched with world-class academic advisors—dedicated to tapping the potential of innate immunity. Complementing this sophisticated biological expertise is a team of deeply experienced small molecule R&D experts with proven track record in discovering and developing transformative medicines. Together, we have created a company culture that is imbued with a sense of urgency in furthering our goal of bringing innovative immunotherapies to patients with inflammation-driven diseases and cancer.